

**PARTNERSHIP HEALTHPLAN OF CALIFORNIA  
POLICY / PROCEDURE**

<b>Policy/Procedure Number:</b> MPUP3047 (previously MCUP3047, UP100347)		<b>Lead Department:</b> Health Services	
		<b>Business Unit:</b> Utilization Management	
<b>Policy/Procedure Title:</b> Tuberculosis Related Treatment		<input checked="" type="checkbox"/> <b>External Policy</b>	
		<input type="checkbox"/> <b>Internal Policy</b>	
<b>Original Date:</b> 07/31/2000		<b>Next Review Date:</b> 06/10/2027	
		<b>Last Review Date:</b> 06/10/2026	
<b>Applies to:</b>	<input type="checkbox"/> <b>Employees</b>	<input checked="" type="checkbox"/> <b>Medi-Cal</b>	<input checked="" type="checkbox"/> <b>Partnership Advantage</b>
<b>Reviewing Entities:</b>	<input checked="" type="checkbox"/> <b>IQI</b>	<input type="checkbox"/> <b>P &amp; T</b>	<input checked="" type="checkbox"/> <b>QUAC</b>
	<input type="checkbox"/> <b>OPERATIONS</b>	<input type="checkbox"/> <b>EXECUTIVE</b>	<input type="checkbox"/> <b>COMPLIANCE</b> <input type="checkbox"/> <b>DEPARTMENT</b>
<b>Approving Entities:</b>	<input type="checkbox"/> <b>BOARD</b>	<input type="checkbox"/> <b>COMPLIANCE</b>	<input type="checkbox"/> <b>FINANCE</b> <input checked="" type="checkbox"/> <b>PAC</b>
	<input type="checkbox"/> <b>CEO</b> <input type="checkbox"/> <b>COO</b>	<input type="checkbox"/> <b>CREDENTIALS</b>	<input type="checkbox"/> <b>DEPT. DIRECTOR/OFFICER</b>
<b>Approval Signature:</b> Robert Moore, MD, MPH, MBA			<b>Approval Date:</b> 06/10/2026

**I. RELATED POLICIES:**

- A. MPQG1005 – Adult Preventive Health Guidelines
- B. MCQG1015 – Pediatric Preventive Health Guidelines
- C. MPQP1048 – Reporting Communicable Diseases
- D. MCCP2035 – Local Health Department (LHD) Coordination

**II. IMPACTED DEPTS:**

- A. Health Services
- B. Claims
- C. Member Services

**III. DEFINITIONS:**

- A. DOT: Directly Observed Therapy or the Direct Observation of the ingestion of prescribed anti-Tuberculosis medications by tuberculosis (TB) infected persons. DOT includes:
  - 1. Delivering of prescribed medications
  - 2. Assisting with the means to ingest prescribed medications
  - 3. Observing the ingestion of prescribed medications
  - 4. Monitoring for signs of non-adherence or adverse side effects
  - 5. Documenting that prescribed medications have been ingested and
  - 6. Reporting compliance and/or other problems
- B. Partnership Advantage: Effective January 1, 2028, Partnership HealthPlan of California will operate a Centers for Medicare & Medicaid Services (CMS)-approved Dual-Eligible Special Needs Plan (D-SNP) in specific counties as described in the Department of Health Care Services (DHCS) CalAIM Dual Eligible Special Needs Plan Policy Guide. This line of business will be known as Partnership Advantage and will be a Medicare Advantage plan offered to all full-benefit, dual-eligible beneficiaries 21 years of age or older who reside in the applicable counties. Partnership Advantage enrollees will be qualified to receive both Medi-Cal and Medicare services as described in the Partnership Advantage Member Handbook.
- C. Tuberculosis (TB) related treatment means all outpatient services necessary for the medical management and follow-up of TB infection and/or active disease. This may include medical therapy, Targeted Case Management (as defined in Title 22, CCR, Section 51276) and DOT when provided by a provider meeting the qualifications (as defined in section 51276.)

**IV. ATTACHMENTS:**

<b>Policy/Procedure Number:</b> MPUP3047 (previously MCUP3047, UP100347)		<b>Lead Department:</b> Health Services <b>Business Unit:</b> Utilization Management	
<b>Policy/Procedure Title:</b> Tuberculosis Related Treatment		<input checked="" type="checkbox"/> <b>External Policy</b> <input type="checkbox"/> <b>Internal Policy</b>	
<b>Original Date:</b> 07/31/2000		<b>Next Review Date:</b> 06/10/2027 <b>Last Review Date:</b> 06/10/2026	
<b>Applies to:</b>	<input type="checkbox"/> <b>Employees</b>	<input checked="" type="checkbox"/> <b>Medi-Cal</b>	<input checked="" type="checkbox"/> <b>Partnership Advantage</b>

A. [TB Screening Guidelines \(Flowchart\)](#)

**V. PURPOSE:**

To define the roles of Partnership HealthPlan of California (Partnership) in providing TB Control and DOT for Medi-Cal and Partnership Advantage beneficiaries.

**VI. POLICY / PROCEDURE:**

A. Program Guidelines:

1. Partnership covers the screening, diagnosis, and follow-up care related to tuberculosis.
  - a. Partnership Medi-Cal: Effective January 1, 2022 with the implementation of Medi-Cal Rx, the pharmacy benefit is carved-out to Medi-Cal Fee-For-Service as described in All Plan Letter (APL) 23-015 and all medications (Rx and OTC) which are provided by a pharmacy must be billed to the State Medi-Cal/ DHCS-contracted pharmacy administrator instead of Partnership. This includes medications used for the treatment of tuberculosis.
  - b. Partnership Advantage: Effective January 1, 2028, the pharmacy benefit for Partnership Advantage enrollees is delegated to a pharmacy benefit manager that will provide medications used for the treatment of tuberculosis.
2. Partnership will reference the current guidelines from the Center for Disease Control and Prevention (CDC), and the American Thoracic Society (ATS). For TB screening, Partnership network providers will use guidelines from the American Academy of Pediatrics (AAP) for persons age 0-20 years and from the United States Preventative Services Taskforce (USPSTF) for adults age 21 or over. The California Department of Public Health (CDPH) TB Risk Assessment Tools should be used to identify adult and pediatric patients at risk for TB.
3. Partnership network providers use laboratories that conform to Title 17, CCR, Section 2505 and CDC and ATS requirements.
4. Partnership Providers shall report all cases of confirmed or suspected active tuberculosis (TB) to the local county health department (LHD) within one day of identification in accordance with Title 17, CCR, Section 2500.

B. Directly Observed Therapy (DOT)

1. Per the California Department of Public Health (CDPH), Directly Observed Therapy (DOT) is a technique of delivering TB treatment to ensure timely completion of treatment, prevent further TB transmission, and prevent development of drug resistance.
2. National guidelines recommend DOT as standard treatment for TB disease.
3. In the event of limited available DOT resources, CDPH provides guidance on groups to be considered for DOT prioritization in their document titled, "[Information for Physicians Regarding Directly Observed Therapy \(DOT\) for Active Tuberculosis \(TB\).](#)"
4. In addition, Partnership Providers are expected to follow any local county health department regulations and instructions regarding the treatment of identified or suspected cases of active tuberculosis not covered by the above language.
5. Since DOT services are provided outside of Partnership's contract with the California Department of Health Care Services (DHCS), a Partnership Referral Authorization Form (RAF) is NOT required, and services will be reimbursed directly by the State of California.
6. The Local Health Department TB Control Program for DOT shall inform the HealthPlan of any changes to policy or of providers failing to refer members needing services.
7. Partnership maintains Memoranda of Understanding (MOUs) with each county it serves to ensure joint case management and care coordination with LHD TB Control Programs. Partnership provides all medically necessary covered services to members with TB on DOT.

<b>Policy/Procedure Number:</b> MPUP3047 (previously MCUP3047, UP100347)		<b>Lead Department:</b> Health Services <b>Business Unit:</b> Utilization Management	
<b>Policy/Procedure Title:</b> Tuberculosis Related Treatment		<input checked="" type="checkbox"/> <b>External Policy</b> <input type="checkbox"/> <b>Internal Policy</b>	
<b>Original Date:</b> 07/31/2000		<b>Next Review Date:</b> 06/10/2027 <b>Last Review Date:</b> 06/10/2026	
<b>Applies to:</b>	<input type="checkbox"/> <b>Employees</b>	<input checked="" type="checkbox"/> <b>Medi-Cal</b>	<input checked="" type="checkbox"/> <b>Partnership Advantage</b>

**VII. REFERENCES:**

- A. Center for Disease Control (CDC) guidelines <https://www.cdc.gov/tb>
- B. Center for Disease Control (CDC) “TB 101 for Health Care Workers <https://www.cdc.gov/tb/webcourses/TB101/page16489.html>
- C. American Thoracic Society (ATS) guidelines <https://www.thoracic.org/statements/tuberculosis-pneumonia.php>
- D. American Academy of Pediatrics (AAP) guidelines <https://www.aap.org/>
- E. United States Preventative Services Taskforce (USPSTF) guidelines <https://www.uspreventiveservicestaskforce.org/uspstf/>
- F. Medi-Cal Provider Manual/ Guidelines: Tuberculosis Program (*tuber*)
- G. Title 17, California Code of Regulations (CCR) [Section 2500](#) and [Section 2505](#)
- H. Title 22, California Code of Regulations (CCR) [Section 51276](#)
- I. DHCS All Plan Letter ([APL 25-013](#)) Medi-Cal Rx Pharmacy Benefits and Cell and Gene Therapy Coverage (09/18/2025)
- J. DHCS All Plan Letter ([APL 23-029](#)) Revised Memorandum of Understanding Requirements for Medi-Cal Managed Care Plans and Third-Party Entities (08/11/2)
  - 1. [Local Health Department Memorandum of Understanding template](#) (DHCS Contract Attachment F)
- K. California Department of Public Health (CDPH) [TB Risk Assessment Tools](#)
- L. California Department of Public Health (CDPH) [Information for Physicians Regarding Directly Observed Therapy \(DOT\) for Active Tuberculosis \(TB\)](#)
- M. California Tuberculosis Controllers Association (CTCA), Latent Tuberculosis Infection Guidance for Preventing Tuberculosis in California, available at: <https://ctca.org/guidelines/guidelines-latent-tuberculosis-infection-guideline/>

**VIII. DISTRIBUTION:**

- A. Partnership Department Directors
- B. Partnership Provider Manual

**IX. POSITION RESPONSIBLE FOR IMPLEMENTING PROCEDURE:** Chief Health Services Officer

**X. REVISION DATES:**

Partnership Advantage (Program effective January 1, 2028)  
06/11/25; 6/10/26

Medi-Cal:

09/19/01; 10/16/02; 10/20/04; 10/19/05, 10/18/06; 10/17/07; 10/15/08, 01/20/10; 01/18/12; 05/20/15; 04/20/16; 04/19/17; \*06/13/18; 05/08/19; 05/13/20; 05/12/21; 05/11/22; 04/12/23; 05/08/24; 06/11/25; 06/10/26

\*Through 2017, Approval Date reflective of the Quality/Utilization Advisory Committee meeting date. Effective January 2018, Approval Date reflects that of the Physician Advisory Committee’s meeting date.

**PREVIOUSLY APPLIED TO:** N/A

\*\*\*\*\*

In accordance with the California Health and Safety Code, Section 1363.5, this policy was developed with

<b>Policy/Procedure Number:</b> MPUP3047 (previously MCUP3047, UP100347)		<b>Lead Department:</b> Health Services <b>Business Unit:</b> Utilization Management	
<b>Policy/Procedure Title:</b> Tuberculosis Related Treatment		<input checked="" type="checkbox"/> <b>External Policy</b> <input type="checkbox"/> <b>Internal Policy</b>	
<b>Original Date:</b> 07/31/2000		<b>Next Review Date:</b> 06/10/2027 <b>Last Review Date:</b> 06/10/2026	
<b>Applies to:</b>	<input type="checkbox"/> <b>Employees</b>	<input checked="" type="checkbox"/> <b>Medi-Cal</b>	<input checked="" type="checkbox"/> <b>Partnership Advantage</b>

involvement from actively practicing health care providers and meets these provisions:

- Consistent with sound clinical principles and processes
- Evaluated and updated at least annually
- If used as the basis of a decision to modify, delay or deny services in a specific case, the criteria will be disclosed to the provider and/or enrollee upon request

The materials provided are guidelines used by Partnership to authorize, modify or deny services for persons with similar illnesses or conditions. Specific care and treatment may vary depending on individual need and the benefits covered under Partnership.

Partnership's authorization requirements comply with the requirements for parity in mental health and substance use disorder benefits in 42 CFR 438.910.